Abstract 921P
Background
Incidence of oropharyngeal squamous cell carcinoma (OPSCC) increases due to rise in human papilloma virus (HPV) related cancers. The tumor microenvironment (TME) of HPV+ OPSCC is characterized as more immune tolerant, with higher density of tumor-infiltrating lymphocytes (TILs). The role of tumor-associated macrophages (TAMs) remains unclear. M2-like TAMs are correlated with impaired overall survival (OS) in other tumor types. This study characterizes the prognostic impact of M2-like TAMs in OPSCC.
Methods
Fifty-eight patients with primary OPSCC, undergoing definite treatment (surgery, radiotherapy, chemoradiotherapy or a combination), were included. FFPE samples were stained for P16, TILs (CD3, CD8, FOXP3) and TAMs (CD68, CD163 and CD206) markers. Semi-quantitative assessment of each marker, in the tumor nest(t) and stroma(s), was executed by a board certified pathologist. Survival estimates were calculated via the Kaplan-Meier method using the log-rank test, using the ad hoc calculated cut-off point. Uni- and multivariate analysis were performed via cox proportional hazard model.
Results
The median density of sCD3, sCD8, tCD68 and sCD206 TAMs was higher in P16+, compared to P16–, whereas FOXP3 and CD163 infiltration was similar according to P16 status. In univariate analysis, tumors with high leukocyte infiltrates (sTIL, sCD8, tCD8, sFOXP3, tCD68, sCD206) had a better overall survival (OS), whereas sTIL-high and tCD8-high were the only factors associated with DFS. High tCD68 (HR 0.19) and sCD206 (HR 0.40) were associated with improved OS in P16+ OPSCC, but not in P16-. sCD163 and tCD163 infiltration was not related to adverse outcomes in P16+ nor in P16-. Table: 921P
Clinical and immunohistochemical characteristics
| P16- | P16+ | p value | |
| N | 39 | 19 | |
| mean Age (y, SD) | 58.8y (8.0) | 59.8y (8.8) | 0.65 |
| mDFS (months, 95%CI) | 14.4m (7.8-48)* | 158m (30-NR)* | ConclusionsIn this study, high tCD68 and sCD206 expression was associated with a better OS in OPSCC, albeit only in P16+ tumors. No concordance was found between CD163 and CD206 expression and both had a different prognostic impact. This illustrates the complexity of TIL-TAM interplay and the TAM spectrum diversity. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyGhent University Hospital. FundingGhent University Hospital Fonds voor Innovatie en Klinisch Onderzoek (FIKO). DisclosureM. Saerens: Financial Interests, Institutional, Invited Speaker: Pierre-Fabre, BMS, MSD; Financial Interests, Institutional, Advisory Board: Novartis, MSD. S. Rottey: Financial Interests, Institutional, Advisory Board: Pfizer, Merck, Roche, Ipsen, BMS; Financial Interests, Institutional, Invited Speaker: Ipsen, BMS, Astellas; Financial Interests, Institutional, Research Grant: MSD, Roche, BMS; Non-Financial Interests, Principal Investigator, It is my main task in the hospital to attract and perform clinical trials in oncology phase I-III: all companies performing clinical trials in oncology in Europe. All other authors have declared no conflicts of interest. Resources from the same session1046P - Genetic alteration profile and T Cell receptor repertoire in severe immune-related adverse events during checkpoint immunotherapyPresenter: Yi Hu Session: Poster session 03 Resources: Abstract 1047P - Tocilizumab is an effective secondary prophylaxis during immune checkpoint inhibitor rechallenge following arthritisPresenter: Michel Obeid Session: Poster session 03 1048P - Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: Evidence from a Belgian real-world multicenter studyPresenter: Danielle Delombaerde Session: Poster session 03 1049P - Cytokine release syndrome in patients treated with bispecific T cell engagers and bispecific monoclonal antibodies at The Christie: A retrospective studyPresenter: Mariam Shalaby Session: Poster session 03 1050P - Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAEPresenter: Sarah Roffeis Session: Poster session 03 1051P - Impact of TLS status on outcomes in patients with high TMB or MSI-high status treated with immune checkpoint inhibitorsPresenter: Antoine Italiano Session: Poster session 03 Resources: Abstract 1052P - Pan-cancer, multi-omic analysis of 'hot' and 'cold' tumors reveals immunotherapy relevant signaturesPresenter: Elisabetta Nale Session: Poster session 03 1053P - The prognostic value of systemic inflammatory markers among patients receiving immune checkpoint inhibitors (ICIs): A population-based studyPresenter: Abdulrahman Alghabban Session: Poster session 03 1054P - CRUCIAL: Analysis of the incidence of second primary cancers in the Spanish thoracic tumor registry according to treatmentPresenter: Mariano Provencio Pulla Session: Poster session 03 1055P - Analysis of correlation between quality of life (QoL) results and survival outcomes in phase III clinical trials testing immunotherapy in metastatic cancersPresenter: Annarita Avanzo Session: Poster session 03 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|